Company news

Agenus Inc. news in 2021

Agenus Inc.'s news releases, calls and decks from 2021, newest first.

View company

Agenus Corporate Update and Third Quarter 2021 Financial Report

November 8, 2021

Agenus to Provide Corporate Update and Third Quarter 2021 Financial Report

October 24, 2021

Agenus Provides Update on Balstilimab Development

October 21, 2021

Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispecific Antibody

October 11, 2021

Agenus Corporate Update and Second Quarter 2021 Financial Report

August 8, 2021

Agenus to Provide Corporate Update and Second Quarter 2021 Financial Report

July 25, 2021

Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777

July 5, 2021

Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer

June 16, 2021

Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus’ Anti-TIGIT Bispecific Antibody Program

May 17, 2021

Agenus Corporate Update and First Quarter 2021 Financial Report

May 5, 2021

Agenus to Provide Corporate Update and First Quarter 2021 Financial Report

April 21, 2021

Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer

April 18, 2021

Agenus Doses First Cancer Patient with iNKT Cell Therapy

April 13, 2021

Agenus Corporate Update and Fourth Quarter & Full Year 2020 Financial Report

March 14, 2021

Agenus Announces Agenus Insights - Virtual R&D Miniseries

February 8, 2021

Agenus Announces Positive Preliminary Results of iNKT Cell Therapy Trial in COVID-19

February 3, 2021

Calls in 2021

Decks in 2021